Skip to content
The Nexus
DossierENTITY

squamous non-small cell lung cancer

Coverage of squamous non-small cell lung cancer in the Nexus archive.

Earliest in view: May 31 · 12:00 UTCMost recent: May 31 · 12:00 UTC
Co-mentioned in this coverage
Akeso Therapeuticsorganization1Summit Therapeuticsorganization1ivonescimabtopic1American Society of Clinical Oncologyorganization1The Lancetorganization1Robert Dugganperson1
Recent coverage
  • HEALTHMay 31 · 12:00 UTCSTAT NEWS
    STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

    Ivonescimab, developed by Akeso Therapeutics and Summit Therapeutics, reduced the risk of death by 34% in patients with squamous non-small cell lung cancer compared to standard treatment in a China-based clinical trial. Results were presented at the American Society of Clinical Oncology meeting and published in The Lancet, with Summit’s co-CEO highlighting the drug’s potential business value.

squamous non-small cell lung cancer · Dossier · The Nexus